THE EFFICACY OF COMBINING ADVANCED PLATELET-RICH FIBRIN TO BIPHASIC ALLOPLAST IN MANAGEMENT OF INTRABONY DEFECTS (RANDOMIZED CONTROLLED CLINICAL TRIAL)

Document Type : Original Article

Authors

1 Instructor at Oral Medicine, Periodontology, Oral Diagnosis and Radiology Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt.

2 Professor of Oral Medicine, Periodontology, Oral Diagnosis and Radiology Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt.

3 Instructor at public health Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt.

Abstract

Introduction: Advanced platelet-rich fibrin (A-PRF) is one of the most recently developed platelet concentrates and believed to have a great impact in regeneration for its richness in leukocytes, platelets, stem cells and cytokines. Biphasic calcium phosphate (BCP) alloplast is a well-known synthetic bone substitute widely used in periodontal regeneration.
Objectives: To evaluate the additive effect of A-PRF to BCP in regeneration of intrabony defects.
Material and Methods: Twenty two interproximal, intrabony defects in 22 patients with moderate to severe chronic periodontitis were allocated to one of the two groups of this study. Group I (test) was treated with open flap debridement followed by placing A-PRF and BCP with a ratio of 1:1, while group II (control) was filled only by BCP mixed with saline after open flap debridement (OFD). Plaque index (PI), modified gingival index (MGI), probing depth (PD) and clinical attachment level (CAL) were evaluated at baseline, 3, 6 and 9 months.
Results: Compared to baseline all evaluated parameters showed improvement at the end of the study in both groups. Changes from baseline to 9 months in A-PRF/BCP group were insignificantly greater compared to BCP/saline group regarding reduction of PI (0.54±0.72 vs 0.53±0.92), MGI (0.34±0.68 vs 0.32±0.78), PD (2.27±0.71mm vs 2.04±0.96mm) and CAL gain (2.13±1.02mm vs 1.68±1.23mm). However, intergroup differences were insignificant.
Conclusions: Based on results of this study, combining advanced platelet-rich fibrin to biphasic alloplast mixture was more advantageous than using BCP alone in intrabony defect management.

Keywords

Main Subjects

References

  1. Raitapuro-Murray T, Molleson T, Hughes F. The prevalence of periodontal disease in a Romano-British population c. 200-400 AD. Br dent J. 2014;217:459.
  2. Flemmig TF. Periodontitis. Annals of Periodontology. Ann Periodontol.1999;4:32-7.
  3. Löe H. Periodontal disease: the sixth complication of diabetes mellitus. Diabetes care. 1993;16:329-34.
  4. Gokhale ST, Dwarakanath CD. The use of a natural osteoconductive porous bone mineral (Bio-Oss) in infrabony periodontal defects. J Indian Soc Periodontol. 2012 Apr;16:247-52.
  5. Cortellini P, Tonetti MS. Regenerative Periodontal Therapy. In: Lindhe J, Lang NP, Karring T, editors. Clinical Periodontology and Implant Dentistry.1. 5th ed: Wiley; 2008: 901 -44.
  6. KARRING T, Nyman S, Gottlow J, Laurell L. Development of the biological concept of guided tissue regeneration—animal and human studies. Periodontol 2000. 1993;1:26-35.
  7. Esposito M, Grusovin MG, Papanikolaou N, Coulthard P, Worthington HV. Enamel matrix derivative (Emdogain) for periodontal tissue regeneration in intrabony defects. A Cochrane systematic review. Eur J Oral Implantol. 2009;2.
  8. Bennett NT, Schultz GS. Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am J Surg. 1993;165:728-37.
  9. Pontoriero R, Wennström J, Lindhe J. The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects. A prospective controlled clinical study. J Clin Periodontol. 1999;26:833-40.
  10. Agrawal AA. Evolution, current status and advances in application of platelet concentrate in periodontics and implantology. World J clin Cases. 2017;5:159.
  11. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62:489-96.
  12. Anfossi G, Trovati M, Mularoni E, Massucco P, Calcamuggi G, Emanuelli G. Influence of propranolol on platelet aggregation and thromboxane B2 production from platelet-rich plasma and whole blood. Prostaglandins Leukot Essent Fatty Acids. 1989;36:1-7.
  13. Choukroun J, Adda F, Schoeffler C, Vervelle A. Une opportunité en paro-implantologie: le PRF. Implantodontie. 2001;42:e62.
  14. Choukroun J, Aalam AA, Miron RJ. Platelet Rich Fibrin “PRF” and Regenerative Medicine:‘The Low-Speed Concept’. MSCs and Innovative Biomaterials in Dentistry: Springer; 2017: 21-42.
  15. Choukroun J. Advanced PRF, & i-PRF: platelet concentrates or blood concentrates. J Periodontal Med Clin Pract. 2014;1:3.
  16. Masuki H, Okudera T, Watanebe T, Suzuki M, Nishiyama K, Okudera H, et al. Growth factor and pro-inflammatory cytokine contents in platelet-rich plasma (PRP), plasma rich in growth factors (PRGF), advanced platelet-rich fibrin (A-PRF), and concentrated growth factors (CGF). Int J Implant Dent. 2016;2:19.
  17. Ghanaati S, Booms P, Orlowska A, Kubesch A, Lorenz J, Rutkowski J, et al. Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. J Oral Implantol. 2014;40:679-89.
  18. Kobayashi E, Flückiger L. Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Investig. 2016;20:2353-60.
  19. Tsai C-H, Shen S-Y, Zhao J-H, Chang Y-C. Plateletrich fibrin modulates cell proliferation of human periodontally related cells in vitro. J Dent Sci. 2009;4:130-5.
  20. Younger EM, Chapman MW. Morbidity at bone graft donor sites. J Orthop Trauma. 1989;3:192-5.
  21. Garrido CA, Lobo SE, Turíbio FM, LeGeros RZ. Biphasic calcium phosphate bioceramics for orthopaedic reconstructions: clinical outcomes. Int J Biomater. 2011;2011:129727.
  22. World Medical A. World medical association declaration of helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-4.
  23. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.
  24. O'Leary TJ, Drake RB, Naylor JE. The plaque control record. J periodontol. 1972;43:38-.
  25. Glavind L, Löe H. Errors in the clinical assessment of periodontal destruction. J periodontal Res. 1967;2:180-4.
  26. Löe H. The gingival index, the plaque index and the retention index systems. J periodontol. 1967;38(6 Part II):610-6.
  27. Lobene R, Weatherford T, Ross N, Lamm R, Menaker L. A modified gingival index for use in clinical trials. Clin prev Dent. 1986;8:3-6.
  28. Ghasemi A, Zahediasl S. Normality tests for statistical analysis: a guide for non-statisticians. Int J Endocrinol Metab. 2012;10:486.
  29. Box GE. Non-normality and tests on variances. Biometrika. 1953;40:318-35.
  30. Heck RH, Tabata L, Thomas SL. Multilevel and longitudinal modeling with IBM SPSS: Routledge; 2013.
  31. Pradeep A, Bajaj P, Rao NS, Agarwal E, Naik SB. Platelet‐Rich Fibrin Combined With a Porous Hydroxyapatite Graft for the Treatment of 3‐Wall Intrabony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial. J periodontol. 2017;88:1288-96.
  32. Ashawan PJ, Zade R. Comparative evaluation of bioactive glass bone graft material with platelet rich fibrin and bioactive glass bone graft material alone for the treatment of periodontal intrabony defects: a clinical and radiographic study. Int J Res Med Sci. 2017;4:3288-94.
  33. Agrawal I, Chandran S, Nadig P. Comparative evaluation of the efficacy of platelet-rich fibrin and calcium phosphosilicate putty alone and in combination in the treatment of intrabony defects: A randomized clinical and radiographic study. Contemp Clin Dent.2017;8:205.
  34. Naqvi A, Gopalakrishnan D, Bhasin MT, Sharma N, Haider K, Martande S. Comparative evaluation of bioactive glass putty and platelet rich fibrin in the treatment of human periodontal intrabony defects: a randomized control trial. J Clin Diagn Res. 2017;11:ZC09–ZC13.
  35. Bodhare GH, Kolte AP, Kolte RA, Shirke PY. Clinical and radiographic evaluation and comparison of bioactive bone alloplast morsels when used alone and in combination with Platelet‐Rich fibrin in the treatment of periodontal intrabony defects–A randomized controlled trial. J periodontol. 2018;00:1- 11.
  36. Agarwal A, Gupta ND, Jain A. Platelet rich fibrin combined with decalcified freeze-dried bone allograft for the treatment of human intrabony periodontal defects: a randomized split mouth clinical trail. Acta Odontol Scand. 2016;74:36-43.
  37. Sezgin Y, Uraz A, Taner IL, ÇULHAOĞLU R. Effects of platelet-rich fibrin on healing of intra-bony defects treated with anorganic bovine bone mineral. Braz Oral Res. 2017;31:e15.
  38. Stein JM, Fickl S, Yekta SS, Hoischen U, Ocklenburg C, Smeets R. Clinical evaluation of a biphasic calcium composite grafting material in the treatment of human periodontal intrabony defects: A 12‐month randomized controlled clinical trial. J Periodontol. 2009;80:1774- 82.
  39. Lee M-J, Kim B-O, Yu S-J. Clinical evaluation of a biphasic calcium phosphate grafting material in the treatment of human periodontal intrabony defects. J periodontal Implant Sci. 2012;42:127-35.
  40. Stevanović M, Biočanin V, Nedić M, Ignjatović N. Efficacy of nanocrystalline bone substitute biphasic calcium phosphate/poly-DL-lactide-co-glycolide for periodontal intrabony defects filling. Vojnosanit Pregle. 2015;72:689-95.

Files

Share

How to cite

Statistics